SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2024, on October 31, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on October 31, 2024.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at . Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at or listen in by dialing the U.S. toll free number (888) 800-8770 or international +1 (646) 307-1953. Conference ID: 7568777. A recorded version of the call will be available on the website approximately two hours after the completion of the event and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir's clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs. Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors on its website.
Media
Arran Attridge
Senior Vice President, Corporate Communications
aattridge@vir.bio
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
Source: Vir Biotechnology, Inc. 舊金山--(美國商業資訊)--Vir Biotechnology, Inc.(納斯達克股票代碼:VIR)今天宣佈,該公司將於2024年10月31日提供公司最新情況並報告截至2024年9月30日的第三季度財務業績。該公司將於2024年10月31日太平洋時間下午 1:30 /美國東部時間下午 4:30 舉行電話會議。
公司最新動態和財務業績將在市場收盤後通過新聞稿提供,並可在Vir網站投資者部分的新聞稿中查閱,網址爲。參與者可以通過Vir網站活動和演示頁面上的網絡直播觀看電話會議,也可以撥打美國免費電話(888)800-8770 或國際+1(646)307-1953收聽。會議編號:7568777。電話會議的錄音版本將在活動結束大約兩小時後在網站上公佈,並將在那裏存檔30天。
關於 Vir 生物技術有限公司
Vir Biotechnology, Inc. 是一家處於臨床階段的生物製藥公司,致力於通過發現和開發治療嚴重傳染病和癌症的藥物來推動免疫系統改變生活。Vir的臨床階段產品組合包括針對慢性三角型肝炎和慢性乙型肝炎感染的傳染病項目,以及多個腫瘤學項目。Vir還擁有一系列針對其他傳染病和腫瘤惡性腫瘤的臨床前項目。Vir定期在其網站上發佈可能對投資者很重要的信息。
媒體
艾倫·阿特里奇
企業傳播高級副總裁
aattridge@vir.bio
投資者
理查德·萊普克
投資者關係高級董事
rlepke@vir.bio
資料來源:Vir 生物技術有限公司